Business Description
OSE Immunotherapeutics SA
ISIN : FR0012127173
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.8 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.22 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.19 | |||||
Beneish M-Score | 3.78 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -44.6 | |||||
3-Year EBITDA Growth Rate | 8.8 | |||||
3-Year EPS without NRI Growth Rate | -3.6 | |||||
3-Year FCF Growth Rate | 7 | |||||
3-Year Book Growth Rate | -32.2 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.23 | |||||
9-Day RSI | 62.81 | |||||
14-Day RSI | 62.53 | |||||
6-1 Month Momentum % | 18.77 | |||||
12-1 Month Momentum % | 17.5 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.62 | |||||
Quick Ratio | 1.62 | |||||
Cash Ratio | 0.99 | |||||
Days Sales Outstanding | 88.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 | |||||
Shareholder Yield % | 4.01 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1032.15 | |||||
Net Margin % | -1032.91 | |||||
FCF Margin % | -887.47 | |||||
ROE % | -88.29 | |||||
ROA % | -27.14 | |||||
ROIC % | -37.17 | |||||
ROC (Joel Greenblatt) % | -467.62 | |||||
ROCE % | -31.12 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 4.85 | |||||
PS Ratio | 48.35 | |||||
PB Ratio | 5.23 | |||||
EV-to-EBIT | -5.06 | |||||
EV-to-Forward-EBIT | -5.92 | |||||
EV-to-EBITDA | -6.06 | |||||
EV-to-Forward-EBITDA | 3.69 | |||||
EV-to-Revenue | 47.28 | |||||
EV-to-Forward-Revenue | 1.85 | |||||
EV-to-FCF | -5.33 | |||||
Earnings Yield (Greenblatt) % | -19.76 | |||||
FCF Yield % | -16.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
OSE Immunotherapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2.227 | ||
EPS (TTM) (€) | -1.18 | ||
Beta | 0.65 | ||
Volatility % | 65.77 | ||
14-Day RSI | 62.53 | ||
14-Day ATR (€) | 0.310491 | ||
20-Day SMA (€) | 5.08975 | ||
12-1 Month Momentum % | 17.5 | ||
52-Week Range (€) | 2.705 - 7.31 | ||
Shares Outstanding (Mil) | 21.6 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
OSE Immunotherapeutics SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
OSE Immunotherapeutics SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
OSE Immunotherapeutics SA Frequently Asked Questions
What is OSE Immunotherapeutics SA(XPAR:OSE)'s stock price today?
When is next earnings date of OSE Immunotherapeutics SA(XPAR:OSE)?
Does OSE Immunotherapeutics SA(XPAR:OSE) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |